Table 1 Patients treated with Octagam® 10 % across three Canadian institutions with corresponding indication group, and disease
Indication group | Disease | Number of patients | Total number of patients |
|---|---|---|---|
Immunology | Primary immune deficiency | 36 | 58 |
Secondary immune deficiency | 10 | ||
Acute antibody mediated rejection | 6 | ||
Desensitization for kidney transplantation | 4 | ||
Secondary immune deficiency due to malignancy | 2 | ||
Hematology | Idiopathic thrombocytopenic purpura | 36 | 38 |
Hemophagocytic lymphohistiocytosis | 1 | ||
Pancytopenia/general weakness | 1 | ||
Neurology | Guillain-Barré syndrome | 7 | 23 |
Myasthenia Gravis | 3 | ||
Chronic inflammatory demyelinating polyneuropathy | 3 | ||
Stiff person syndrome | 2 | ||
Acute disseminated encephalomyelitis | 2 | ||
Multifocal motor neuropathy | 1 | ||
Acute sensimotor polyneuropathy | 1 | ||
Amyotrophic lateral sclerosis | 1 | ||
Opsoclonus-myoclonus | 1 | ||
Presumed neurosarcoidosis | 1 | ||
Limbic encephalitis | 1 | ||
Rheumatology | Dermatomyositis | 6 | 7 |
Juvenile dermatomyositis | 1 | ||
Infectious disease | Group A streptococcus fasciitis | 2 | 4 |
Staphylococcal toxic shock | 1 | ||
Cellulitis | 1 | ||
Miscellaneous | Pneumonia query tuberculosis, post coronary artery bypass graft surgery, septic shock, dental/gum problem | 5 | 5 |